

References

I-191

1. Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. *J Clin Oncol*. 2017;35(35):3898-3905.
2. Mensah FA, Blaize J-P, Bryan LJ. Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date. *Onco Targets & Ther*. 2018;11:48174827.
3. Copanlisib Hydrochloride In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated date January 7, 2019.
4. Clinical Pharmacology™ 2022. Tampa FL: Gold Standard, Inc. Copanlisib.
5. Micromedex DrugDex Compendium®. 2022. Copanlisib (Aliqopa).
6. National Comprehensive Cancer Network (NCCN). NCCN Drugs and Biologics Compendium®. 2022.
7. Aliqopa® (copanlisib), injection, for intravenous use [package insert]. Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ. Revised 2/2022.